Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06138873 · ClinicalTrials.gov registry record · NA

Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy

A NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy, sponsored by Rush University Medical Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
5
Study locations

NCT06138873 is a NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 100 participants, below the 285-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (65% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06138873, a NA study of Ventricular Tachycardia and Ischemic Cardiomyopathy, is actively recruiting participants, sponsored by Rush University Medical Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
5
Study locations

Study Summary

Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.

Interventions

  • PROCEDURE Ablation-index guided ventricular tachycardia ablation
  • PROCEDURE Ventricular tachycardia ablation with no AI-guidance

Study Locations (5)

Illinois

  • Rush University Medical Center - Chicago

Massachusetts

  • Mass General Brigham and Women's Hospital - Boston

Michigan

  • Medical University of Michigan - Ann Arbor

Minnesota

  • Mayo Clinic - Rochester

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-10-23
Est. Completion 2027-11-23
Phase NA

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT06138873

The ClinicalTrials.gov registry entry for NCT06138873 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 28 other Ventricular Tachycardia trials with a reported enrollment target (65% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ventricular Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Ablation-index guided ventricular tachycardia ablation is the first listed.

NCT06138873 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT06138873 about?

NCT06138873 is a clinical study titled "Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy". Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality h...

What is the current status of trial NCT06138873?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2024-10-23. Estimated completion is 2027-11-23.

What conditions does trial NCT06138873 study?

This clinical trial studies the following conditions: Ventricular Tachycardia, Ischemic Cardiomyopathy.

What interventions are being tested in trial NCT06138873?

The interventions under investigation include: Ablation-index guided ventricular tachycardia ablation (PROCEDURE), Ventricular tachycardia ablation with no AI-guidance (PROCEDURE).

Who is sponsoring clinical trial NCT06138873?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06138873 being conducted?

This trial has 5 study locations across Illinois, Massachusetts, Michigan, Minnesota, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ventricular Tachycardia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.